Integrating GFAP Improves Accuracy of Large Vessel Occlusion Detection in Acute Stroke Settings | NeurologyLive

Integrating GFAP Improves Accuracy of Large Vessel Occlusion Detection in Acute Stroke Settings | NeurologyLive

January 25, 2026 discoverhiddenusacom Business

A new study suggests a potential improvement in the rapid diagnosis of stroke, a condition where every minute counts. Researchers have found that combining a quick blood test measuring glial fibrillary acidic protein (GFAP) with existing stroke assessment tools could lead to more accurate identification of large vessel occlusions (LVOs) – a severe type of stroke – and faster access to specialized care.

Improving Stroke Diagnosis

The research, published in STROKE, builds on a larger German study, “DETECT,” conducted between 2022 and 2024. This substudy, dubbed DETECT LVO, retrospectively analyzed data from 353 patients with a mean age of 74.6 years. The goal was to see if adding prehospital GFAP measurements to standard paramedic assessments could enhance the accuracy of LVO detection.

How the Study Worked

Currently, paramedics use several scoring systems – including the Rapid Arterial Occlusion Evaluation, Field Assessment Stroke Triage for Emergency Destination, 3-Item Stroke Scale, Emergency Medical Stroke Assessment, and Cincinnati Prehospital Stroke Scale – to quickly assess stroke risk in the field. DETECT LVO evaluated how these scores performed when combined with GFAP levels measured using a point-of-care platform (i-STAT Alinity Abbott). LVOs were confirmed through CT-angiography, identifying blockages in the internal carotid artery, middle cerebral artery, and basilar artery.

Did You Know? The DETECT LVO study included data from 258 patients experiencing ischemic stroke, with 101 ultimately diagnosed with LVOs.

The study, led by Love-Preet Kalra, MD, of RKH Klinikm Ludwigsburg in Germany, found that integrating GFAP measurements significantly increased the accuracy of all the scoring systems tested. For example, the Field Assessment Stroke Triage for Emergency Destination score improved from 0.859 to 0.899. Similar improvements were seen across the other assessment tools.

Implications for Patient Care

Accurate and rapid LVO detection is critical because these strokes require immediate intervention – specifically, endovascular thrombectomy (EVT) – to remove the blockage and restore blood flow. Faster diagnosis means patients can be transferred directly to specialized centers equipped for EVT, potentially minimizing brain damage and improving outcomes.

Expert Insight: The potential to refine existing stroke assessment protocols with a readily available biomarker like GFAP represents a pragmatic step toward optimizing prehospital triage and ensuring timely access to life-saving interventions.

Recent research also explores potential pharmacological interventions for LVO. A phase 2, investigator-initiated trial examined the use of semaglutide (Ozempic; Novo Nordisk) in conjunction with EVT, finding it safe and well-tolerated, and associated with a lower risk of intracranial hemorrhage. However, the study, published in Nature, did not demonstrate improved functional recovery overall, though an exploratory analysis suggested benefits for patients who did not receive intravenous thrombolysis (IVT).

Frequently Asked Questions

What is a large vessel occlusion?

A large vessel occlusion (LVO) is a severe type of stroke caused by a blockage in one of the major arteries supplying blood to the brain, specifically the internal carotid artery, middle cerebral artery, or basilar artery.

What is GFAP and how is it measured?

GFAP is glial fibrillary acidic protein, a biomarker released into the bloodstream after brain injury, including stroke. In this study, GFAP levels were measured using a point-of-care platform called i-STAT Alinity Abbott.

What was the GALLOP trial investigating?

The GALLOP trial was a phase 2 randomized trial evaluating the use of semaglutide before and after endovascular thrombectomy (EVT) in patients with disabling LVO. The study did not find improved functional recovery overall, but showed the drug was safe and well-tolerated.

Will these findings lead to changes in how stroke patients are treated remains to be seen, but the integration of GFAP testing into prehospital stroke assessment represents a promising avenue for improving diagnostic accuracy and ultimately, patient outcomes.